NCT05696795 is a Phase 2 clinical trial of Abrocitinib 200 mg in Sarcoidosis, sponsored by Yale University.

Who is sponsoring NCT05696795?

NCT05696795 is sponsored by Yale University.

What drugs are being tested in NCT05696795?

Interventions in NCT05696795: Abrocitinib 200 mg.

What condition does NCT05696795 study?

NCT05696795 studies Sarcoidosis.

Is NCT05696795 still recruiting?

NCT05696795 is currently completed. Last updated 16 May 2025.

Last reviewed 2025-05-16 · How we verify

NCT05696795

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Janus Kinase Inhibition in Sarcoidosis

Completed Phase 2 Last updated 16 May 2025

What this trial tests

Phase 2 trial testing Abrocitinib 200 mg in Sarcoidosis in 10 participants. Completed in 23 April 2025.

Timeline

1 June 2023

Primary endpoint
23 April 2025

23 April 2025

Quick facts

Lead sponsor	Yale University
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	1 June 2023
Primary completion	23 April 2025
Estimated completion	23 April 2025
Sites	1 location across United States

Drugs / interventions tested

Abrocitinib 200 mg (abrocitinib-200-mg) — full drug profile →

Conditions studied

Sarcoidosis — all drugs for Sarcoidosis →

Sponsor

Yale University

Who can join

18 and older, any sex, with Sarcoidosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to investigate the role of the oral JAK1 inhibitor, abrocitinib 200 mg once daily, for the treatment of patients with moderate to severe cutaneous sarcoidosis.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

JAK inhibitors and black box warnings: what is the future for JAK inhibitors?
Tokareva K, Reid P, Yang V, Liew D, et al · · 2023 · cited 20× · PMID 37596779 · DOI 10.1080/1744666x.2023.2249237
Molecularly Targeted Therapies for Inflammatory Cutaneous Granulomatous Disorders: A Review of the Evidence and Implications for Understanding Disease Pathogenesis.
Hwang E, Abdelghaffar M, Shields BE, Damsky W. · · 2023 · cited 5× · PMID 37719661 · DOI 10.1016/j.xjidi.2023.100220
Off-label use of abrocitinib in dermatology: A systematic literature review with narrative summary.
Su Z, Sun C, Yao WH, Wang P, et al · · 2026 · PMID 41561201 · DOI 10.1016/j.jdin.2025.11.025

Verify or expand the search:

Other trials of Abrocitinib 200 mg

Trials testing the same drug.

NCT06283550 — Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to · Phase 2 · completed
NCT05650736 — Janus Kinase Inhibition in Granuloma Annulare · Phase 2 · active not recruiting
NCT05375929 — A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India · Phase 3 · completed
NCT04345367 — Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical T · Phase 3 · completed
NCT03422822 — Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and O · Phase 3 · completed

Other recruiting trials for Sarcoidosis

Currently open trials in the same condition.

NCT07498842 — Corticosteroid Tapering in Sarcoidosis · NA · recruiting
NCT07073963 — Virtual Patient Groups for Sarcoidosis Associated Fatigue · NA · recruiting
NCT07384897 — Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung Disease · NA · recruiting
NCT06636487 — Expand Pulmonary Rehabilitation to Other Chronic Respiratory Diseases Than COPD · NA · active not recruiting
NCT06576505 — Immunological Mechanisms in Sarcoidosis · recruiting

Other Yale University trials

Trials by the same sponsor.

NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking · Phase 2 · not yet recruiting
NCT04910984 — Developing a Chatbot to Promote HIV Testing · NA · not yet recruiting
NCT07458087 — Accuracy of the Accuro 3S · NA · not yet recruiting
NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa · Phase 1, PHASE2 · not yet recruiting
NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05696795 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale University
Last refreshed: 16 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05696795.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing